Nucana (NCNA) AI Stock Analysis

• Market Cap: $14.98M
• Dividend Yield: N/A
• Average Volume (3M): 174.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: N/A
• EPS Growth: 94.52%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 1,906,479
• 10 Day Avg. Volume: 84,221
• 30 Day Avg. Volume: 174,327
• PEG Ratio: 1.57
• Price to Book (P/B): 189.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -58.15
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -8
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $3.50 ▲(1.16% Upside)

The score is driven primarily by weak financial performance (no revenue, continued losses, and negative cash flow despite low leverage). Technicals add pressure with a bearish trend (below key moving averages and negative MACD). Valuation offers limited support due to a negative P/E and no dividend yield.

Positive Factors

Proprietary Technology

NuCana's ProTide technology offers a competitive edge by potentially transforming existing chemotherapeutic agents into more effective treatments, which could lead to successful drug development and commercialization.

Cash Management

Strong cash management and low leverage provide financial stability, enabling NuCana to sustain its R&D efforts and navigate the challenges of drug development without immediate financial distress.

Strategic Partnerships

Potential partnerships and collaborations can provide vital funding and resources, enhancing NuCana's ability to advance its drug pipeline and potentially accelerate market entry.

Negative Factors

Lack of Revenue

The absence of revenue generation highlights the risk of financial instability, as the company relies heavily on external funding and successful drug development to achieve future profitability.

Operational Losses

Persistent operational losses without revenue offset strain financial resources, increasing the urgency for successful product development and commercialization to ensure long-term viability.

Equity Decline

Declining equity suggests financial vulnerability, potentially limiting NuCana's ability to raise capital and invest in R&D, which is crucial for advancing its drug pipeline.

Nucana Business Overview & Revenue Model

Company Description

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

How the Company Makes Money

NuCana makes money primarily through the development and commercialization of its proprietary ProTide technology-based drugs. The company's revenue model is focused on advancing its pipeline of product candidates through clinical trials and eventually bringing them to market upon regulatory approval. Additionally, NuCana may generate income through strategic partnerships, licensing agreements, and collaborations with other pharmaceutical companies. These partnerships can provide upfront and milestone payments, as well as royalties on product sales. As a clinical-stage company, NuCana's earnings are currently dependent on its ability to successfully develop and commercialize its drug candidates.

Nucana Financial Statement Overview

Summary

Nucana's financials reflect the challenges faced by biotechnology firms in early development stages, with no revenue generation and consistent losses. While the company demonstrates strong cash management and low leverage, the shrinking equity and continued cash burn highlight financial vulnerabilities. The firm’s financial health would benefit significantly from achieving revenue growth and reducing operational losses.

Income Statement

Nucana's income statement shows no revenue generation over the analyzed period, which is typical for early-stage biotechnology companies. However, the continuous negative EBIT and net income indicate ongoing operational losses without revenue offset.

Balance Sheet

The company's high cash reserves relative to debt showcase prudent cash management, but the consistent decline in stockholders' equity raises concerns. The debt-to-equity ratio remains low, suggesting low financial leverage, yet the reduction in equity suggests potential risks if this trend continues.

Cash Flow

Nucana's cash flow statement reflects substantial negative operating cash flow, indicating cash burn typical of R&D-intensive biotech firms. The company maintains liquidity through financing, but the lack of free cash flow growth suggests an ongoing reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-18.94M	-22.48M	-31.78M	-52.15M	-41.88M	0.00
Net Income	-27.52M	-19.00M	-27.63M	-32.02M	-40.53M	-30.68M
Balance Sheet
Total Assets	32.31M	14.77M	27.81M	58.25M	77.47M	107.79M
Cash, Cash Equivalents and Short-Term Investments	25.25M	6.75M	17.23M	41.91M	60.26M	87.36M
Total Debt	136.00K	190.00K	396.00K	639.00K	371.00K	645.00K
Total Liabilities	6.39M	8.82M	12.92M	19.75M	11.93M	8.56M
Stockholders Equity	25.93M	5.95M	14.89M	38.50M	65.55M	99.23M
Cash Flow
Free Cash Flow	-13.97M	-19.41M	-26.92M	-23.68M	-24.89M	-23.25M
Operating Cash Flow	-13.77M	-19.12M	-26.44M	-23.16M	-23.82M	-21.62M
Investing Cash Flow	47.00K	79.00K	2.89M	120.00K	-3.56M	-1.31M
Financing Cash Flow	27.18M	8.18M	-53.00K	-161.00K	-98.00K	61.80M

Nucana Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NCNA, the sentiment is Negative. The current price of 3.46 is below the 20-day moving average (MA) of 3.60, below the 50-day MA of 3.73, and below the 200-day MA of 29.61, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 46.94 is Neutral, neither overbought nor oversold. The STOCH value of 77.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NCNA.

Nucana Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GLTO	51 Neutral	$32.54M	-1.68	-114.81%	―	―	37.42%
NCNA	46 Neutral	$14.98M	-0.02	-179.40%	―	―	94.52%
APRE	43 Neutral	$6.57M	-0.44	-74.72%	―	-62.75%	23.87%
XBIO	42 Neutral	$5.01M	-1.07	-57.43%	―	13.30%	22.70%
IMRN	38 Underperform	$7.88M	-1.40	-49.00%	―	47.17%	26.84%

Nucana Corporate Events

NuCana Announces Return of CEO Hugh S. Griffith Following Health Leave

On December 15, 2025, NuCana announced the return of Hugh S. Griffith as Chief Executive Officer following his health-related leave of absence, reinstating him as the company’s principal executive officer. Andrew Kay, who had been serving as Executive Chairman and acting CEO during this period, has returned to his role as Chairman of the Board. This leadership update marks a return to continuity for NuCana and is expected to support the company’s strategic operations and bolster stakeholder confidence.

NuCana Showcases Promising Results for NUC-7738 in Melanoma Treatment

On December 10, 2025, NuCana announced the presentation of new clinical data at the ESMO Immuno-Oncology Congress 2025, showcasing the potential of NUC-7738 in treating PD-1 inhibitor-resistant metastatic melanoma. The data demonstrated clinical activity and a favorable safety profile, with partial responses and durable disease control observed in patients. These findings support further clinical advancement and enrollment, potentially leading to a registrational pathway. The study’s positive results were also highlighted in a UK documentary, emphasizing the potential impact on patients who have exhausted current treatment options.

NuCana Reports Q3 2025 Financial Results and Board Resignation

On November 13, 2025, NuCana plc announced its financial results for the third quarter of 2025. The company reported a significant reduction in operating losses compared to the previous year, with a loss of £779,000 for the quarter, down from £5.3 million in the same period in 2024. Despite the improvement, NuCana continues to face financial challenges, with a total comprehensive loss of £267,000 for the quarter. Additionally, the company announced the resignation of Dr. Bali Muralidhar from its Board of Directors, effective October 21, 2025, noting that the resignation was not due to any disagreements with the company.

NuCana Secures Key Patent for NUC-7738 in China

On November 5, 2025, NuCana announced the issuance of a new patent by the China National Intellectual Property Administration for NUC-7738’s composition of matter. This patent strengthens NuCana’s global intellectual property strategy and supports opportunities for innovative cancer therapies in China. The patent is a key milestone in the company’s efforts to address unmet needs in cancer treatment, particularly in combination with pembrolizumab for melanoma patients.

NuCana Presents Promising Data on NUC-7738 at ESMO Congress 2025

On October 18, 2025, NuCana presented promising data at the European Society for Medical Oncology Congress 2025, showcasing the synergistic effects of NUC-7738 in combination with PD-1 inhibitors in treating renal cell carcinoma. The study demonstrated that NUC-7738 enhances the effectiveness of PD-1 inhibitors, potentially offering a new treatment option for cancers resistant to anti-PD-1 therapy. This data reinforces the mechanism of action of NUC-7738 and supports its ongoing clinical development, including the expansion of the Phase 1/2 NuTide:701 study to include more patients with PD-1 inhibitor-resistant melanoma.

NuCana Reports Promising Clinical Data for NUC-3373

On October 14, 2025, NuCana announced new data from the NuTide:303 clinical study, highlighting the efficacy and safety of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab. The study showed promising results, including significant tumor reduction in heavily pre-treated patients with advanced solid tumors. The findings, published in medRxiv and PLOS ONE, suggest that NUC-3373 enhances immune response and tumor cell death, supporting its potential as part of future cancer treatment regimens.

The most recent analyst rating on (NCNA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.